The use of programmed PD-L1 and tumor-infiltrating lymphocytes (TILs) as predictive and prognostic biomarkers is well-recognized and associated with response to immunotherapy, although the latter biomarker is related to pathological specimens often found in the primary tumor site [170,171]. This evidence concerns the gene CD274 and neoplasm.